Literature DB >> 24813597

Genetic variations in the GLUT3 gene associated with myelomeningocele.

Brendan D Connealy1, Hope Northrup2, Kit Sing Au3.   

Abstract

OBJECTIVE: Our objectives were to examine the extent of described sequence variation in the glucose transporter 3 (GLUT3) gene in children with myelomeningocele (MM), identify novel variations in the GLUT3 gene in these children, and determine whether these variations may confer a risk of MM. STUDY
DESIGN: We sequenced the 10 exons of GLUT3, including exon-intron boundaries, on 96 children with MM. Sequencing was performed with Sanger methods and results analyzed with deoxyribonucleic acid analysis software. Frequencies of known single-nucleotide polymorphisms were identified, and those differing from the reference sequence (GRCh37/hg19 assembly) were considered variations.
RESULTS: Six novel and 9 previously described, genetic variations were identified in our population. The novel variations included a large, 83 base pair deletion involving the core promoter region and part of exon 1 (1 of 96 children), and a 2 base pair deletion in the coding sequence of exon 4 (1 of 96 children). The remaining novel variations were located in the introns in the proximity of the splice sites. Novel mutations in GLUT3 were observed among 6.25% of our population. Additionally, the frequency of the rare allele for rs17847972 located in a splice donor site is higher (P < .001) in MM in our population than expected.
CONCLUSION: We identified previously undescribed deletions and single-nucleotide variations involving the GLUT3 gene that may be associated with increased susceptibility to MM. Of particular interest, the 2 deletions involve both an important core promoter site and a coding region predicted to have a deleterious effect. The functional significance of these findings is under investigation.
Copyright © 2014 Mosby, Inc. All rights reserved.

Entities:  

Keywords:  GLUT3 gene; Sanger sequencing; genetic variations; myelomeningocele

Mesh:

Substances:

Year:  2014        PMID: 24813597      PMCID: PMC4149867          DOI: 10.1016/j.ajog.2014.05.013

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  41 in total

1.  Folic acid and pantothenic acid protection against valproic acid-induced neural tube defects in CD-1 mice.

Authors:  Jennifer E Dawson; Angela M Raymond; Louise M Winn
Journal:  Toxicol Appl Pharmacol       Date:  2005-08-22       Impact factor: 4.219

2.  A note on exact tests of Hardy-Weinberg equilibrium.

Authors:  Janis E Wigginton; David J Cutler; Goncalo R Abecasis
Journal:  Am J Hum Genet       Date:  2005-03-23       Impact factor: 11.025

3.  Glucose transporter isoform-3 mutations cause early pregnancy loss and fetal growth restriction.

Authors:  Amit Ganguly; Robert A McKnight; Santanu Raychaudhuri; Bo-Chul Shin; Zhigui Ma; Kelle Moley; Sherin U Devaskar
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-01-09       Impact factor: 4.310

4.  Spinal lesion level in spina bifida: a source of neural and cognitive heterogeneity.

Authors:  Jack M Fletcher; Kim Copeland; Jon A Frederick; Susan E Blaser; Larry A Kramer; Hope Northrup; H Julia Hannay; Michael E Brandt; David J Francis; Grace Villarreal; James M Drake; John P Laurent; Irene Townsend; Susan Inwood; Amy Boudousquie; Maureen Dennis
Journal:  J Neurosurg       Date:  2005-04       Impact factor: 5.115

Review 5.  Human neural tube defects: developmental biology, epidemiology, and genetics.

Authors:  Eric R Detrait; Timothy M George; Heather C Etchevers; John R Gilbert; Michel Vekemans; Marcy C Speer
Journal:  Neurotoxicol Teratol       Date:  2005-03-05       Impact factor: 3.763

Review 6.  Genotoxicity and diabetic embryopathy: impaired expression of developmental control genes as a cause of defective morphogenesis.

Authors:  T I Chang; M R Loeken
Journal:  Semin Reprod Endocrinol       Date:  1999

7.  Genes in glucose metabolism and association with spina bifida.

Authors:  Christina M Davidson; Hope Northrup; Terri M King; Jack M Fletcher; Irene Townsend; Gayle H Tyerman; Kit Sing Au
Journal:  Reprod Sci       Date:  2008-01       Impact factor: 3.060

8.  Risk of neural tube defect-affected pregnancies among obese women.

Authors:  G M Shaw; E M Velie; D Schaffer
Journal:  JAMA       Date:  1996-04-10       Impact factor: 56.272

9.  Nutrient sensing by the early mouse embryo: hexosamine biosynthesis and glucose signaling during preimplantation development.

Authors:  Marie Pantaleon; Jeanie Scott; Peter L Kaye
Journal:  Biol Reprod       Date:  2007-11-28       Impact factor: 4.285

10.  Prevention of diabetes-associated embryopathy by overexpression of the free radical scavenger copper zinc superoxide dismutase in transgenic mouse embryos.

Authors:  Z J Hagay; Y Weiss; I Zusman; M Peled-Kamar; E A Reece; U J Eriksson; Y Groner
Journal:  Am J Obstet Gynecol       Date:  1995-10       Impact factor: 8.661

View more
  4 in total

1.  Neural Deletion of Glucose Transporter Isoform 3 Creates Distinct Postnatal and Adult Neurobehavioral Phenotypes.

Authors:  Bo-Chul Shin; Carlos Cepeda; Ana María Estrada-Sánchez; Michael S Levine; Laya Hodaei; Yun Dai; Jai Jung; Amit Ganguly; Peter Clark; Sherin U Devaskar
Journal:  J Neurosci       Date:  2018-09-19       Impact factor: 6.167

Review 2.  Finding the genetic mechanisms of folate deficiency and neural tube defects-Leaving no stone unturned.

Authors:  Kit Sing Au; Tina O Findley; Hope Northrup
Journal:  Am J Med Genet A       Date:  2017-09-25       Impact factor: 2.802

3.  Association of facilitated glucose transporter 2 gene variants with the myelomeningocele phenotype.

Authors:  Jaclyn E Ruggiero; Hope Northrup; Kit Sing Au
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2015-03-17

4.  Adult glut3 homozygous null mice survive to demonstrate neural excitability and altered neurobehavioral responses reminiscent of neurodevelopmental disorders.

Authors:  Bo-Chul Shin; Carlos Cepeda; Mason Eghbali; Shin Yun Byun; Michael S Levine; Sherin U Devaskar
Journal:  Exp Neurol       Date:  2021-01-19       Impact factor: 5.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.